RARE PEDIATRIC DISEASE VOUCHER PROVIDES BULLISH CASE FOR CELLCEUTIX!

Here is a thought that should literally send shivers down the spine of anyone holding a short position in Cellceutix. The float (available shares) is 77.81 million shares. 77.81 X $1.75 = ~140 million dollars.
So for less than half of what United Therapeutics received for their last Rare Pediatric Disease Priority Review Voucher they could buy up the entire float of Cellceutix. They have a pretty good idea of what that voucher is worth, I bet they might like to have another one to sell in the future. As a free bonus they could be a major share holder in a Company with, the first new class of antibiotic in the last 20 years that is about to begin a world wide Phase 3 trial, a possible treatment for Psoriasis that is wrapping up a phase 2 and is a pill not an injection and is way cheaper than biologics, then there is that Cancer/ oral mucositis drug that could be a blockbuster drug. I'll ignore the pre-clinical compounds (Autism drug etc.)

F1 ASH has provided the perfect spectacles for all to look at CTIX through. Thanks F1. Ella Ruth Below The Article Below

Cellceutix bags Rare Pediatric Disease Designation for Kevetrin for type of eye cancer Dec 1 2015, 12:26 ET | About:

Cellceutix (OTCPK:CTIX +1.2%) announces that it has received Rare Pediatric Disease Designation from the FDA for Orphan Drug-tagged Kevetrin for the treatment of retinoblastoma, a rare type of eye cancer that originates in the retina.

The big benefit of the designation is the opportunity to apply for a Rare Pediatric Disease Review Voucher, which can be used for Priority Review (six months) of a future NDA or can be sold to a third party. The vouchers are quite valuable. In 2014, AbbVie (ABBV +0.6%) bought one from United Therapeutics (UTHR +2.7%) for $350M in cash.

Kevetrin is a small molecule that induces the activation of the tumor suppressor protein p53.